HACKENSACK, New Jersey - (June 5, 2006) - Amorcyte Inc (Amorcyte), a privately funded cell therapy company developing products to treat cardiovascular disease, announced today that its Phase I clinical trial is now open at Emory University School of Medicine, under Arshed A. Quyyumi, M.D., FRCP, FACC, Professor of Medicine, Cardiology, and is expected to open in another center within 90 days. “In many ways this is an important and unique Phase I trial for the developing field of cell therapies for cardiovascular disease”, states Dr. Quyyumi. “In addition to safety, this trial will assess the effect of stem cell dose on definitive clinical endpoints following administration after myocardial infarction.”
